Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings

Key Points

• Vor Biopharma shares fell 6.5% to about $22.05 after the company reported quarterly EPS of negative $0.80, missing the consensus estimate of negative $0.69. Trading volume was significantly below average.
• Analyst sentiment remains mixed but generally positive: the stock carries a “Moderate Buy” consensus rating and an average price target of $42.25, despite recent neutral and sell-rating actions.
• Institutional investors own approximately 97.29% of the company, with several firms recently initiating or increasing positions. Vor is developing engineered, off-the-shelf cell therapies, including its lead VOR33 program for AML and high-risk MDS.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report)'s share price traded down 6.5% during trading on Wednesday following a dissappointing earnings announcement. The company traded as low as $22.13 and last traded at $22.0450. 173,608 shares were traded during mid-day trading, a decline of 84% from the average session volume of 1,065,662 shares. The stock had previously closed at $23.59.

The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11).

Analyst Upgrades and Downgrades

VOR has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and issued a $31.00 target price on shares of Vor Biopharma in a research note on Monday, May 18th. Wedbush boosted their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a "neutral" rating in a research report on Thursday, May 14th. Weiss Ratings upgraded Vor Biopharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, June 30th. Wall Street Zen cut Vor Biopharma from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. Finally, Jefferies Financial Group raised shares of Vor Biopharma to a "strong-buy" rating in a research report on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $42.25.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Vor Biopharma during the fourth quarter worth approximately $36,000. Bank of America Corp DE grew its holdings in Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company's stock worth $232,000 after acquiring an additional 4,144 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Vor Biopharma in the 3rd quarter worth about $230,000. BNP Paribas Financial Markets raised its stake in shares of Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock valued at $296,000 after purchasing an additional 5,058 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Vor Biopharma in the 3rd quarter valued at about $304,000. Institutional investors and hedge funds own 97.29% of the company's stock.

Vor Biopharma Stock Performance

The firm's 50-day moving average price is $18.00 and its 200 day moving average price is $15.88.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source